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Gliosarcomas are rare tumours of the central nervous
system, with a well-known capacity for metastasis. When
they metastasise, the dissemination occurs more
frequently via the haematogenous route to extraneural
sites. Metastasis-spread through the cerebrospinal fluid
is extremely rare. We present the case of a 58-year-old
man who underwent a gross total resection of a lesion
in the left temporal lobe. The histological findings
revealed a gliosarcoma and the patient received
radiotherapy followed by chemotherapy. Seven months
after surgery, while the patient remained neurologically
intact, brain and spinal cord MRI revealed tumour
recurrence and neuroaxis metastases through the traffic
routes of the cerebrospinal fluid. The patient died
8 months after the diagnosis. A PubMed search
regarding metastatic gliosarcoma up to June 2015 was
also carried out. To the best of our knowledge, this is
the first case report of gliosarcoma metastases to the
brain and spinal cord leptomeninges.
BACKGROUND
Gliosarcomas were first described in 1895 as glio-
blastomas with a sarcomatous component.1 The
current definition is based on the 2007 WHO clas-
sification, which considers them well-defined brain
lesions with a clearly identifiable biphasic pattern
of glial and mesenchymal components.2
Gliosarcomas comprise 0.48% of all intracranial
tumours and 2–8% of glioblastomas.3 They prefer-
entially affect individuals between the sixth and
seventh decades of life, with a male:female ratio of
1.4–1.8:1.4 5 The most frequent locations, in des-
cending order, are the temporal, frontal, parietal
and occipital lobes.6
Clinical features depend on the location of the
tumour and are similar to those of glioblastomas.
The most common symptoms are headache, vomit-
ing, seizures, hemiparesis, cognitive decline and
other symptoms associated with intracranial hyper-
tension.4 The imaging features are variable. They
may present with central necrotic areas and hetero-
geneous contrast uptake similar to a glioblastoma,
or with homogeneous contrast enhancement and
well-defined margins similar to a meningioma.4 5
Histologically, two distinct cell populations can be
identified, one composed of neoplastic astrocytes
meeting the criteria for glioblastoma and the other
consisting of a spindle cell sarcomatous compo-
nent.7 The glial component exhibits strong staining
for glial fibrillar acidic protein (GFAP), unlike the
GFAP-negative sarcoma-like component.
The metastatic capacity of gliosarcomas is well
known with an incidence that can reach 11%,
which is much higher than that for glioblastomas
(0.2–1.2%).8 As far back as 1958, some authors
have reported cases of metastasis with mixed
elements, namely glial and sarcomatous.5
Subsequently, Smith et al observed two cases of
Figure 1 Preoperative brain MRIs. (A) Gadolinium-enhanced T1-weighted axial image showing a lesion in the left
temporal lobe with heterogeneous contrast uptake. (B) Fluid-attenuated inversion recovery axial image showing
tumoural infiltration/oedema in the surrounding brain parenchyma.
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metastasis that were composed only of sarcomatous cells, raising
the possibility that the metastatic potential of gliosarcoma is
linked to its sarcomatous component.5 The greater propensity
of gliosarcoma for metastasis could also be related to its
frequent temporal location, near the dura and venous sinuses.1
The major sites of metastasis are lungs, liver and lymph nodes.8
Other reported sites are the spleen, adrenal glands, kidneys, oral
mucosa, skin, bone marrow, skull, ribs and spine.5 Metastatic
disease is more common in young male individuals who have
undergone adjuvant radiotherapy.9
Beaumont et al reported a case involving a gliosarcoma with
multiple extracranial metastases and intravascular tumour
emboli revealed in the postmortem examination. This is consist-
ent with a greater propensity for haematogenous dissemination.9
The increased capacity for haematogenous metastasis is also
related to the fact that sarcomatous tumours have a higher ten-
dency to spread using this pathway.1 However, there are other
routes of spread, such as metastasis through the cerebrospinal
fluid, where the tumour cells reach the subarachnoid space or
ventricular cavities through the leptomeninges or transependy-
maly.10 In these cases, ventricular, cranial nerve, spinal cord and
leptomeningeal invasion can occur.1
Regarding the therapeutic approach to gliosarcoma, there are
no specific protocols. The first review published in the literature
considered a number of clinical and biological similarities with
glioblastomas, and since then they have been treated using the
same protocols; these involve maximum surgical removal fol-
lowed by radiotherapy and chemotherapy.11 12 In the presence
of metastasis, the ideal treatment remains unknown but the
common chemotherapy regimens for soft tissue sarcomas seem
to offer no benefit.8 Even with treatment, the survival times of
patients with gliosarcoma are short and range from 6 to
14.8 months.1
Figure 2 Postoperative brain MRI. Gadolinium-enhanced T1-weighted
axial image demonstrating radical tumour excision.
Figure 3 Histological tissue sections.
(A) H&E showing a biphasic tumour
with glial (left) and fusiform (right)
cells (×40 original magnification). (B)
Glial fibrillar acidic protein with strong
immunoreactivity in the glial
component (left) and virtually no
staining in the mesenchymal tissue
(right; ×40 original magnification).
Figure 4 MRIs of the control brain at
7 months after craniotomy.
Gadolinium-enhanced T1-weighted
coronal images showing: (A)
leptomeningeal spread with multiple
parenchyma and meningeal deposits,
(B) one of which involves the right
trigeminal nerve.
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Figure 5 Vertebrospinal MRI at
7 months after craniotomy.
Gadolinium-enhanced T1-weighted
sagittal images revealing: (A)
retroclival enhancement, diffuse
meningeal spread, and nodular lesions
in the C5 and (B) along the cauda
equina nerve roots, indicative of ‘drop’
metastases.
Table 1 Reports on metastatic gliosarcomas published until June 2015
Author Year Sex
Age
(years) Localisation Type Resection
Adjuvant
treatment Metastasis location Metastasis histology
Survival
(months)
Ehrenreich13 1958 M 44 Parietal P Unknown RT Lung Mixed 8
Feigin14 1958 M 6 Temporal P Unknown Unknown Lung Mixed 15
Garret15 1958 F 55 Temporal P Radical RT Lymph nodes Mixed 9
Smith16 1969 M 49 Frontal P Partial RT+CT Liver Sarcomatous 8
Smith16 1969 M 44 Temporal P Partial RT Liver Mixed 8
Smith16 1969 M 58 Temporal P Biopsy RT Liver, lung Sarcomatous 8
Smith16 1969 M 63 Temporal P Partial Unknown Lung, liver, adrenal gland Mixed 8
Smith16 1969 M 64 Temporal P Partial Unknown Liver, lung Mixed 11
Smith16 1969 M 6 Temporal P Biopsy RT Lung Mixed 13
Smith16 1969 F 63 Frontal P Partial Unknown Vertebrae, lung Mixed 11
Slowik17 1980 F 46 Parietal S Unknown RT Lung, liver, kidney, lymph nodes Mixed 19
Ojeda18 1984 F 83 Frontal P Not
operated
None Lung Sarcomatous 3
Weaver19 1984 M 63 Parietal S Biopsy RT Lung, omentum Sarcomatous 7
Cerame20 1985 F 11 Temporal P Unknown RT+CT Lung Mixed 1
Yokoyama21 1985 F 22 Occipital P Radical RT+CT Lung, pleura, lymph nodes, bone
marrow, liver
Mixed 4
Matsuyama22 1989 M 68 Temporal P Radical RT+CT Liver, spleen, spinal cord, scalp Mixed 5
Gjerdrum23 1999 M 61 Temporo-parietal P Unknown RT Oral mucosa, palpebra, lung Sarcomatous 6
Witwer10 2000 M 48 Temporal P Radical RT+CT Spinal cord Unknown 3





Beaumont9 2007 M 47 Temporal S Radical RT+CT+G Thyroid, chest wall, pleura, lung,
pericardium, myocardium, diaphragm,
pancreas, liver, scalp, spleen, kidney,
stomach, lip mucosa
Sarcomatous 20
Fischer25 2007 M 50 Multifocal P Biopsy RT+CT Spinal cord Mixed 5
Demirci1 2008 F 68 Frontal P Radical RT Spinal cord Sarcomatous 10
Maeda26 2010 F 51 Temporal P Radical RT+CT Lung Unknown 5
Mesfin27 2010 F 51 Temporal P Radical RT+CT+G Lung Mixed 17
Rapp28 2011 M 67 Temporooccipital P Unknown RT+CT Lung, skeletal system Mixed 12
Chen29 2012 F 31 Temporal P Unknown RT+CT Liver, lymph nodes, spinal cord, lung,
scalp, neck soft tissue, ileum, humeri,
collarbone
Mixed 92
Dawar8 2013 F 57 Temporal S Radical RT+CT Lung, pleura, lymph nodes Mixed 64
Mansouri30 2013 M 62 Frontal P Radical RT+CT Brain leptomeninges and dura Mixed Unknown
Oberndorfer31 2013 M 37 Temporal S Radical RT+CT Diaphragm Sarcomatous 11
Asencio-Cortés32 2014 F 48 Frontotemporal P Radical RT+CT Spinal cord Unknown 15
Schindler33 2014 F 64 Frontal S Radical RT+CT Spinal cord Sarcomatous 23
Resection refers to the first surgery. Adjuvant treatment and survival refers to patients with secondary gliosarcomas after initial diagnosis of the primary tumour as glioblastoma.
CT, chemotherapy; F, female; G, Gliadel; M, male; P, primary; RT, radiotherapy; S, secondary.
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CASE PRESENTATION
A 58-year-old man with no relevant clinical history presented
with bilateral tinnitus, which had developed over a 2-week
period. Neurological examination on admission revealed no
abnormalities.
INVESTIGATIONS
The patient’s symptoms encouraged investigation using brain
CT, and a lesion in the left temporal lobe was detected. In MRI,
the lesion measured 32×30 mm, and had ill-defined contrast
enhancement, central necrotic areas and marked vasogenic
oedema; it caused a small uncal herniation (figure 1).
TREATMENT
The patient underwent pterional craniotomy with radical
tumour excision (figure 2). The surgery was performed without
complications and the patient remained neurologically intact.
Histological examination revealed a gliosarcoma, according to
the WHO criteria (figure 3). Adjuvant treatments were carried
out. Radiotherapy was given in 30 fractions, five times a week,
to a total dose of 60 Gy, and a chemotherapy regimen consisting
of temozolomide (Stupp protocol) was instituted.
OUTCOME AND FOLLOW-UP
At 7 months after surgery, the patient’s neurological status
remained unchanged; MRI examination was performed on the
control brain. The study revealed tumour recurrence and menin-
geal, parenchymal and perineural spread (figure 4). As a result
of these findings, an MRI scan of the spinal cord and a thora-
coabdominopelvic CT scan were carried out. The MRI revealed
meningeal spread and ‘drop’ metastases in the C5 and the cauda
equina nerve roots (figure 5), consistent with dissemination
through the traffic routes of the cerebrospinal fluid. The thora-
coabdominopelvic CT scan revealed no suspect tumoural
lesions. It was decided to interrupt chemotherapy because of
the leptomeningeal dissemination and a gradual deterioration in
the neurological status of the patient. The patient died at
8 months after surgery.
DISCUSSION
A PubMed search of studies published up until June 2015, using
the term ‘gliosarcoma’, revealed 31 cases of metastatic gliosar-
coma (table 1). Three additional case reports have been pub-
lished but we were unable to access the full-text articles. Of the
cases, the vast majority reported on haematogenous spread and
subsequent visceral metastasis. Nevertheless, in eight patients,
there may have been spread through the traffic routes of the
cerebrospinal fluid to the spinal cord or leptomeninges. The
present case might be the ninth to report cerebrospinal fluid dis-
semination, the second with metastasis to the leptomeninges,
and the first with simultaneous spread to the leptomeninges of
the brain and spinal cord.
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